Oncopeptides AB Namn-Aktier o.N.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
21.15%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.09 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 0.139 G | 0 Units |
| PRICE DETERMINATION TIME | 06/24/2026 / 09:57:01 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 0.1461 | 0.1388 |
| PREV. DAY'S PRICE | 0.1415 | (06/23) |
| CHANGE DAY BEFORE | -0.00 | -1.77 % |
| 52 WEEK HIGH / LOW | 0.5293 (10/07) | 0.1104 (05/12) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | -0.02 | -0.04 | -0.09 | -0.13 | -0.15 |
| DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.00 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | - | - | - | - | - |
| PRICE - BOOK RATIO | - | - | - | 6.17 | 12.20 |
| PRICE - SALES RATIO | - | - | 15.34 | 8.18 | 19.66 |
| PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2DLU2 |
| ISIN | SE0009414576 |
| SYMBOL | OND |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ONCOPEPTIDES AB O.N. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -1.56 % | -2.46 % | 2.51 % | -62.70 % | 21.15 % | -73.96 % | -97.49 % | -66.37 % |
| HIGH | 0.15 | 0.19 | 0.19 | 0.42 | 0.53 | 0.56 | 6.11 | 0.42 |
| LOW | 0.14 | 0.14 | 0.11 | 0.11 | 0.11 | 0.10 | 0.10 | 0.11 |
Dividend
per share
ONCOPEPTIDES AB O.N. does not deliver dividend information
Company profile
Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The firm focuses on its product candidate melflufen, a peptide conjugated alkylator, belonging to a new class of drugs called peptidase enhanced cytotoxics, which targets aminopeptidases and rapidly releases alkylating agents into tumor cells. The company was founded by Rolf Larsson, Rolf Lewensohn, Joachim Gullbo, Kristina Luthman, Hans Ehrsson, and Peter Nygren on September 5, 2000 and is headquartered in Stockholm, Sweden.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.